SEATTLE — NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of $55 million of its common stock. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock.

The bookrunning managers of the offering are J. P. Morgan and Morgan Stanley, and the co-managers are Leerink Partners and Robert W. Baird & Co. Incorporated.

The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

A registration statement relating to this offering of common stock has been filed but has not been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

CONTACT: Investor Contact:

Lynn Pieper of Westwicke Partners

For NanoString Technologies

lynn.pieper@westwicke.com

415-202-5678

Media Contact:

Nicole Litchfield

For NanoString Technologies

nicole@bioscribe.com

415-793-6468

Source: NanoString Technologies, Inc.